During the past decade, Oncology Institute of Vojvodina conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 11 clinical trials were completed, i.e. on average, 68.8% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 4 clinical trials were completed. i.e. 57.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Oncology Institute of Vojvodina" #1 sponsor was "Hoffmann-La Roche" with 10 trials, followed by "Pfizer" with 3 trials sponsored, "Aileron Therapeutics, Inc." with 1 trials sponsored, "Arbeitsgemeinschaft medikamentoese Tumortherapie" with 1 trials sponsored and "Can-Fite BioPharma" with 1 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Oncology Institute of Vojvodina" #1 collaborator was "Bristol-Myers Squibb" with 1 trials as a collaborator, "European Organisation for Research and Treatment of Cancer - EORTC" with 1 trials as a collaborator, "European Society of Surgical Oncology" with 1 trials as a collaborator, "German Breast Group" with 1 trials as a collaborator and "Hoffmann-La Roche" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Oncology Institute of Vojvodina" are "Metastatic Breast Cancer" (3 trials), "Bladder Cancer" (2 trials), "Breast Neoplasms" (2 trials), "Melanoma" (2 trials) and "Urothelial Carcinoma" (2 trials). Many other conditions were trialed in "Oncology Institute of Vojvodina" in a lesser frequency.

Most popular intervention types in "Oncology Institute of Vojvodina" are "Drug" (21 trials), "Other" (4 trials), "Biological" (3 trials), "Procedure" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Atezolizumab" (3 trials), "Paclitaxel" (3 trials), "Carboplatin" (2 trials) and "Docetaxel" (2 trials). Other intervention names were less common.

The vast majority of trials in "Oncology Institute of Vojvodina" are 24 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Oncology Institute of Vojvodina". 1 are not yet recruiting, 6 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Oncology Institute of Vojvodina, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Oncology Institute of Vojvodina, 1 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".

Oncology Institute of Vojvodina has several departments that took part in Clinical trials: "Institute for Cardiovascular Diseases of Vojvodina" - 17 trials, "Institut za onkologiju Vojvodine" - 2 trials